Page 180 - 2021_02-Haematologica-web

T. Yahata et al.
mobilization of hematopoietic stem and
progenitor cells: a dynamic multi-facet process. Cambridge, MA: The Stem Cell Research Community, StemBook.; p1-37.
34.Krause DS, Lazarides K, Lewis JB, von Andrian UH, Van Etten RA. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood. 2014; 123(9):1361-1371.
35. Chen Y, Kelm RJ, Budd RC, Sobel BE, Schneider DJ. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem. 2004;92(1):178-188.
36. Placencio VR, Ichimura A, Miyata T, DeClerck YA. Small molecule inhibitors of plasminogen activator inhibitor-1 elicit anti- tumorigenic and anti-angiogenic activity. PLoS One. 2015;10(7):e0133786.
37. Mashiko S, Kitatani K, Toyoshima M, et al. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther. 2015; 16(2):253-260.
38. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002;30(9):973-981.
39. Borthakur G, Kantarjian H, Wang X, et al.
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimu- lating factor results in improved event-free survival. Cancer. 2008;113(11):3181-3185.
40. Holtz M, Forman SJ, Bhatia R. Growth fac- tor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 2007;67(3):1113-1120.
41. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119(17):3917-3924.
42. Beider K, Darash-Yahana M, Blaier O, et al. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protec- tive effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther. 2014; 13(5):1155-1169.
43. Godavarthy PS, Kumar R, Herkt SC, et al. The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis. Haematologica. 2020;105(1):136-147.
44. Izuhara Y, Takahashi S, Nangaku M, et al. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol. 2008;28(4):672-677.
45. Izuhara Y, Yamaoka N, Kodama H, et al. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman pri- mates. J Cereb Blood Flow Metab. 2010; 30(5):904-912.
46. Eren M, Boe AE, Murphy SB, et al. PAI-1-reg- ulated extracellular proteolysis governs senes- cence and survival in Klotho mice. Proc Natl Acad Sci U S A. 2014;111(19):7090-7095.
47. Boe AE, Eren M, Murphy SB, et al. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vas- cular senescence. Circulation. 2013; 128(21): 2318-2324.
48. Pelisch N, Dan T, Ichimura A, et al. Plasminogen activator inhibitor-1 antagonist TM5484 attenuates demyelination and axonal degeneration in a mice model of mul- tiple sclerosis. PLoS One. 2015;10(4): e0124510.
49. Ibrahim AA, Yahata T, Onizuka M, et al. Inhibition of plasminogen activator inhibitor type-1 activity enhances rapid and sustain- able hematopoietic regeneration. Stem Cells. 2014;32(4):946-958.
50. Eren M, Place AT, Thomas PM, Flevaris P, Miyata T, Vaughan DE. PAI-1 is a critical regulator of FGF23 homeostasis. Sci Adv. 2017;3(9):e1603259.
494
haematologica | 2021; 106(2)